ArticleJournal of scleroderma and related disorders2024
Can machine learning assist in systemic sclerosis diagnosis and management? A scoping review.
Article in Journal of scleroderma and related disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review aims to summarize the existing literature on how machine learning can be used to impact systemic sclerosis diagnosis, management, and treatment. Following Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) reporting guidelines, Embase, Web of Science, Medline (PubMed), IEEE Xplore, and ACM Digital Library were searched from inception to 3 March 2024, for primary literature reporting on machine learning models in any capacity regarding scleroderma. Following robust triaging, 11 retrospective studies were included in this scoping review. Three studies focused on the diagnosis of scleroderma to influence preferred management and nine studies on treatment and predicting treatment response to scleroderma. Nine studies used supervision in their machine learning model training; two used supervised and unsupervised training and one used solely unsupervised training. A total of 817 patients were included in the data sets. Seven of the included articles used patients from the United States, one from Belgium, two from Japan, and two from China. Although currently limited to retrospective studies, the results indicate that machine learning modeling may have a role in early diagnosis, management, therapeutic decision-making, and in the development of future therapies for systemic sclerosis. Prospective studies examining the use of machine learning in clinical practice are recommended to confirm the utility of machine learning in patients with systemic sclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.